Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Long term treatment with stimulant laxatives - clinical evidence for effectiveness and safety?

Research output: Contribution to journalReviewResearchpeer-review

  1. Gastric cancer and gastrin: on the interaction of Helicobacter pylori gastritis and acid inhibitory induced hypergastrinemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Plasma calprotectin is superior to serum calprotectin as a biomarker of intestinal inflammation in ulcerative colitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The microbiome reflects diagnosis and predicts disease severity in paediatric onset inflammatory bowel disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Systematic review with meta-analyses: does the pathogen matter in post-infectious irritable bowel syndrome?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review

    Research output: Contribution to journalReviewResearchpeer-review

  2. Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men without Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Do callers to out-of-hours care misuse an option to jump the phone queue?

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Discrepancies Between the Medication List in Electronic Prescribing Systems and Patients' Actual Use of Medicines

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVES: Bisacodyl and sodium picosulfate are classified both as stimulant laxatives, approved for short-term treatment of constipation and sold without prescription (OTC). Stimulant laxatives are associated with harmful long-term colonic effects and possible carcinogenic risk - and evidence support that these agents are used for longer periods. We aimed to compile and review the clinical trial evidence describing the effectiveness and safety of long-term treatment (>14 continuous days) with stimulant laxatives.

METHODS: The PubMed database was searched for all randomised clinical trials (RCTs) examining the effect of bisacodyl or sodium picosulfate in adult patients diagnosed with constipation.

RESULTS: Five RCTs (one open-label and four double-blinded) with intervention periods of four weeks duration were eligible. These included 1008 patients, whereof 26% dropped out. A positive global assessment of efficacy was obtained in 78-99% of the patients treated with bisacodyl or sodium picosulfate. Notably, the same global assessment was obtained in 46-54% of the placebo-treated patients. Compared to placebo, an improvement in stool consistency and a significant increase in number of bowel movements peer week were seen in favor of bisacodyl and sodium picosulfate. However, for pyridostigmine, a significant difference was seen compared to bisacodyl. AEs were generally mild, but frequent (up to 72%) mostly diarrhea and abdominal pain.

CONCLUSION: The evidence base does not support use of stimulant laxatives for more than four weeks. Due to the substantial use of stimulant laxatives including sold OTC, longer term RCTs and epidemiological studies investigating effects and safety on the longer term are warranted.

Original languageEnglish
JournalScandinavian Journal of Gastroenterology
Volume54
Issue number1
Pages (from-to)27-34
Number of pages8
ISSN0036-5521
DOIs
Publication statusPublished - 31 Jan 2019

    Research areas

  • Constipation, effectiveness, long-term treatment, safety, stimulant laxatives, Bisacodyl/adverse effects, Humans, Citrates/adverse effects, Constipation/drug therapy, Long-Term Care, Picolines/adverse effects, Randomized Controlled Trials as Topic, Laxatives/adverse effects, Colon/drug effects, Organometallic Compounds/adverse effects

ID: 56643437